These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1383408)

  • 21. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
    Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
    J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [T-cell-induced prevention of HSV-1 keratitis by immunization with the synthetic peptide of glycoprotein D].
    Heiligenhaus A; Berra A; Dutt JE; Zhao TZ; Wells PA; Foster CS
    Ophthalmologe; 1994 Oct; 91(5):608-16. PubMed ID: 7812092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of glycoprotein D of herpes simplex virus type 1 in a recombinant baculovirus: protective responses and T cell recognition of the recombinant-infected cell extracts.
    Krishna S; Blacklaws BA; Overton HA; Bishop DH; Nash AA
    J Gen Virol; 1989 Jul; 70 ( Pt 7)():1805-14. PubMed ID: 2544667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections.
    Soleimanjahi H; Roostaee MH; Rasaee MJ; Mahboudi F; Kazemnejad A; Bamdad T; Zandi K
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):100-6. PubMed ID: 16420602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
    Nass PH; Elkins KL; Weir JP
    J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B.
    Kohl S; Strynadka NC; Hodges RS; Pereira L
    J Clin Invest; 1990 Jul; 86(1):273-8. PubMed ID: 2164044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.
    Geerligs HJ; Weijer WJ; Welling GW; Welling-Wester S
    J Immunol Methods; 1989 Nov; 124(1):95-102. PubMed ID: 2553820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
    Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
    Ritchie MH; Oakes JE; Lausch RN
    Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2460-8. PubMed ID: 8392037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.
    Hu K; He X; Yu F; Yuan X; Hu W; Liu C; Zhao F; Dou J
    Immunol Invest; 2011; 40(3):265-78. PubMed ID: 21204603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
    Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
    J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
    Ghiasi H; Bahri S; Nesburn AB; Wechsler SL
    Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1352-60. PubMed ID: 7775113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
    Martin S; Rouse BT
    J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baculovirus-expressed glycoprotein E (gE) of herpes simplex virus type-1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge.
    Ghiasi H; Kaiwar R; Nesburn AB; Slanina S; Wechsler SL
    Virology; 1992 Jun; 188(2):469-76. PubMed ID: 1585630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
    Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
    Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection.
    Caselli E; Grandi P; Argnani R; Balboni PG; Selvatici R; Manservigi R
    Intervirology; 2001; 44(1):1-7. PubMed ID: 11223713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro.
    Weijer WJ; Drijfhout JW; Geerligs HJ; Bloemhoff W; Feijlbrief M; Bos CA; Hoogerhout P; Kerling KE; Popken-Boer T; Slopsema K
    J Virol; 1988 Feb; 62(2):501-10. PubMed ID: 2826811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D.
    Wachsman M; Luo JH; Aurelian L; Paoletti E
    Vaccine; 1992; 10(7):447-54. PubMed ID: 1376951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Native HSV glycoprotein D subunit vaccine: analysis of in vitro T-cell activation and antigen presentation.
    Ishizaka ST; Mishkin EM
    Viral Immunol; 1991; 4(3):187-93. PubMed ID: 1667262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.